About this Research Topic
Traditional vaccination strategies, utilizing inactivated viral, bacterial, and toxoid preparations or live-attenuated strains, have successfully controlled diseases such as tetanus and polio. Safer formulations composed of purified polysaccharides or recombinant proteins yielded effective vaccines against pathogens such as Streptococcus pneumoniae and Hepatitis B virus. Nonetheless, the large majority of pathogens causing significant human morbidity and mortality across the globe, such as Mycobacterium tuberculosis, HIV, and Plasmodium falciparum, have evaded eradication by modern vaccine approaches. Newer vaccine technologies are urgently needed to combat these and other emerging infectious organisms. This research topic welcomes original research or review articles addressing innovative vaccine development against human pathogens. Areas of interest include but are not limited to: novel adjuvants; nanotechnology; delivery systems; alternative delivery routes (i.e. transcutaneous, intradermal); and vaccine manufacturing. Vaccine strategies utilizing a multi-antigen expression platform are of particular interest.
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
